Frontiers in Pharmacology (Nov 2021)

Recent Advances in Pharmaceutical Cocrystals: From Bench to Market

  • Ravi Kumar Bandaru,
  • Smruti Rekha Rout,
  • Gowtham Kenguva,
  • Bapi Gorain,
  • Nabil A. Alhakamy,
  • Nabil A. Alhakamy,
  • Prashant Kesharwani,
  • Rambabu Dandela

DOI
https://doi.org/10.3389/fphar.2021.780582
Journal volume & issue
Vol. 12

Abstract

Read online

The pharmacokinetics profile of active pharmaceutical ingredients (APIs) in the solid pharmaceutical dosage forms is largely dependent on the solid-state characteristics of the chemicals to understand the physicochemical properties by particle size, size distribution, surface area, solubility, stability, porosity, thermal properties, etc. The formation of salts, solvates, and polymorphs are the conventional strategies for altering the solid characteristics of pharmaceutical compounds, but they have their own limitations. Cocrystallization approach was established as an alternative method for tuning the solubility, permeability, and processability of APIs by introducing another compatible molecule/s into the crystal structure without affecting its therapeutic efficacy to successfully develop the formulation with the desired pharmacokinetic profile. In the present review, we have grossly focused on cocrystallization, particularly at different stages of development, from design to production. Furthermore, we have also discussed regulatory guidelines for pharmaceutical industries and challenges associated with the design, development and production of pharmaceutical cocrystals with commercially available cocrystal-based products.

Keywords